跳转至内容
Merck
CN

P-007

PCP(苯环利定)标准液 溶液

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

别名:

苯环利定

登录 查看组织和合同定价。

选择尺寸

关于此项目

经验公式（希尔记法）:
C17H25N
化学文摘社编号:
77-10-1
分子量:
243.39
UNSPSC Code:
41116107
PubChem Substance ID:
329820005
NACRES:
NA.24
MDL number:
MFCD00055598

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

PCP(苯环利定)标准液 溶液, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

SMILES string

N3(CCCCC3)C2(CCCCC2)c1ccccc1

InChI

1S/C17H25N/c1-4-10-16(11-5-1)17(12-6-2-7-13-17)18-14-8-3-9-15-18/h1,4-5,10-11H,2-3,6-9,12-15H2

InChI key

JTJMJGYZQZDUJJ-UHFFFAOYSA-N

grade

certified reference material

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

drug control

Narcotic Licence Schedule A (Switzerland); psicótropo (Spain); Decreto Lei 15/93: Tabela IIA (Portugal); Pszichotróp anyag / Psychotropic Substance (Hungary), 78/2022. (XII. 28.) BM rendelet
kontrollierte Droge in Deutschland

Quality Level

300

concentration

1.0 mg/mL in methanol

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

forensics and toxicology

format

single component solution

storage temp.

2-8°C

相关类别

General description

苯环利啶，通常称为PCP，是一种具有致幻作用和神经毒性作用的娱乐性药物。 PCP具有“天使尘埃”或“wet”之类的街道名称，呈粉末或液体形式。非法形式的药物通常喷雾至多叶材料（例如大麻）上，然后进行抽吸。此认证溶液标准品可作为校准物和对照品中的起始材料，通过LC/MS或GC/MS，用于从法医分析和临床毒理学到尿液药物测试方面的各种应用中。

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
German
Dieses Produkt fällt unter das Betäubungsmittelgesetz (BtMG). Für eine Bestellung dieses Produktes ist eine Erlaubnis nach § 3 BtMG zwingend erforderlich, es sei denn, es greift eine Ausnahme von der Erlaubnispflicht nach § 4 oder § 26 BtMG.

English
This product is subject to the German Narcotics Act. A permit under Section 3 of the German Narcotics Act is mandatory for ordering this product unless an exemption from the permit requirement under Section 4 or Section 26 of the German Narcotics Act applies.

signalword

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

target_organs

Eyes,Central nervous system

存储类别

3 - Flammable liquids

wgk

WGK 2

flash_point_f

49.5 °F - closed cup

flash_point_c

9.7 °C - closed cup

法规信息

监管及禁止进口产品
此项目有

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

G P Misselbrook et al.
Acute medicine, 11(3), 157-160 (2012-09-21)
Methoxydine (4-MeO-PCP) and Methoxetamine (3-MeO-2-Oxo-PCE) are both commercially produced designer drugs with structural and biochemical similarities to phencyclidine (PCP). Although phencyclidine toxicity is well documented, its recreational use in present times is rare. With the advent of new designer drugs
[Preliminary comparative study on the usefulness of instant-view'TM M-1 and Triage DOA in testing for drugs-of-abuse in forensic urine samples].
Fumio Moriya
Chudoku kenkyu : Chudoku Kenkyukai jun kikanshi = The Japanese journal of toxicology, 25(3), 243-246 (2012-10-13)
James W Price
Journal of addiction medicine, 7(2), 129-132 (2013-02-02)
This study examines the effect of creatinine normalization on urine drug concentrations of 5 substances (amphetamines, cocaine, marijuana, opiates, and phencyclidine) and how this affects the proportion of reported positives. The Wilcoxon matched-pairs signed-ranks test was used to compare the
Ross Zimnisky et al.
Psychopharmacology, 226(1), 91-100 (2012-10-20)
A major challenge in the pharmacological treatment of psychotic disorders is the effective management of the associated cognitive dysfunctions. Novel concepts emphasize a potential benefit of partial agonists acting upon dopamine D(2)-like receptors in ameliorating these cognitive deficits, and pre-clinical
Masakuni Horiguchi et al.
Behavioural brain research, 238, 36-43 (2012-09-29)
Development of dopamine (DA) D(1) receptor agonists is a priority to improve cognitive impairment in schizophrenia (CIS). This study examined the dose-response relationship of the selective D(1) agonist, SKF38393 (0.5-40 mg/kg), to reverse the deficit in novel object recognition (NOR)
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持